| Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats C Partovian, S Adnot, B Raffestin, V Louzier, M Levame, IM Mavier, ... American Journal of Respiratory Cell and Molecular Biology 23 (6), 762-771, 2000 | 238 | 2000 |
| Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension C Partovian, S Adnot, S Eddahibi, E Teiger, M Levame, P Dreyfus, ... American Journal of Physiology-Heart and Circulatory Physiology 275 (6 …, 1998 | 211 | 1998 |
| Regulation of protein kinase B/Akt activity and Ser 473 phosphorylation by protein kinase Cα in endothelial cells C Partovian, M Simons Cellular signalling 16 (8), 951-957, 2004 | 153 | 2004 |
| Syndecan-4 regulates subcellular localization of mTOR complex2 and Akt activation in a PKCα-dependent manner in endothelial cells C Partovian, R Ju, ZW Zhuang, KA Martin, M Simons Molecular cell 32 (1), 140-149, 2008 | 134 | 2008 |
| Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension: effect of prostacyclin therapy S Eddahibi, M Humbert, S Sediame, C Chouaid, C Partovian, B Maitre, ... American journal of respiratory and critical care medicine 162 (4), 1493-1499, 2000 | 128 | 2000 |
| PKCα activates eNOS and increases arterial blood flow in vivo C Partovian, Z Zhuang, K Moodie, M Lin, N Ouchi, WC Sessa, K Walsh, ... Circulation research 97 (5), 482-487, 2005 | 118 | 2005 |
| PKC Activates eNOS and Increases Arterial Blood Flow In Vivo C Partovian, Z Zhuang, K Moodie, M Lin, N Ouchi, WC Sessa, K Walsh, ... | 118* | |
| Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission LI Horwitz, C Partovian, Z Lin, JN Grady, J Herrin, M Conover, J Montague, ... Annals of internal medicine 161 (10_Supplement), S66-S75, 2014 | 108 | 2014 |
| Hospital-wide (all-condition) 30-day risk-standardized readmission measure L Horwitz, C Partovian, Z Lin, J Herrin, J Grady, M Conover, J Montague, ... Yale New Haven Health Services Corporation/Center for Outcomes Research …, 2011 | 97 | 2011 |
| Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin C Partovian, A Benetos, JP Pommiès, W Mischler, ME Safar American Journal of Physiology-Heart and Circulatory Physiology 274 (5 …, 1998 | 89 | 1998 |
| Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? B Bikdeli, KM Strait, K Dharmarajan, C Partovian, SG Coca, N Kim, SX Li, ... Journal of the American College of Cardiology 61 (14), 1549-1550, 2013 | 81 | 2013 |
| Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo Y Zhang, J Li, C Partovian, FW Sellke, M Simons American Journal of Physiology-Heart and Circulatory Physiology 284 (6 …, 2003 | 73 | 2003 |
| Hospital-wide all-cause unplanned readmission measure: final technical report L Horwitz, C Partovian, Z Lin, J Herrin, J Grady, M Conover Baltimore, MD: Centers for Medicare & Medicaid Services, 2012 | 53 | 2012 |
| Intravenous fluids in acute decompensated heart failure B Bikdeli, KM Strait, K Dharmarajan, SX Li, P Mody, C Partovian, SG Coca, ... JACC: Heart Failure 3 (2), 127-133, 2015 | 46 | 2015 |
| Hospital patterns of use of positive inotropic agents in patients with heart failure C Partovian, SR Gleim, PS Mody, SX Li, H Wang, KM Strait, LA Allen, ... Journal of the American College of Cardiology 60 (15), 1402-1409, 2012 | 32 | 2012 |
| Hospital variation in intravenous inotrope use for patients hospitalized with heart failure insights from get with the guidelines LA Allen, GC Fonarow, MV Grau-Sepulveda, AF Hernandez, PN Peterson, ... Circulation: Heart Failure 7 (2), 251-260, 2014 | 26 | 2014 |
| Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. FBC Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P Clin Pharmacol Ther. 58 (3), 257-63, 1995 | 19 | 1995 |
| Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans C Partovian, E Jacqz‐Aigrain, A Keundjian, P Jaillon, C Funck‐Brentano Clinical Pharmacology & Therapeutics 58 (3), 257-263, 1995 | 19 | 1995 |
| Development of a hospital outcome measure intended for use with electronic health records: 30-day risk-standardized mortality after acute myocardial infarction RL McNamara, Y Wang, C Partovian, J Montague, P Mody, E Eddy, ... Medical care 53 (9), 818-826, 2015 | 18 | 2015 |
| Spending more, doing more, or both? An alternative method for quantifying utilization during hospitalizations T Lagu, HM Krumholz, K Dharmarajan, C Partovian, N Kim, PS Mody, ... Journal of hospital medicine 8 (7), 373-379, 2013 | 17 | 2013 |
